Deltanoid Pharmaceuticals, Inc. Announces Appointment Of Douglas Jermasek As Chief Executive Officer

MADISON, Wis., Feb. 2, 2016 /PRNewswire-USNewswire/ -- Deltanoid Pharmaceuticals, Inc. today announced the appointment of former Genzyme/Sanofi renal head, Douglas Jermasek as its new Chief Executive Officer. Co-founder Hector F DeLuca, PhD, MD, DSC will continue as Chairman of the Board of Directors and assume the responsibilities of President and Chief Operating Officer. Co-founder Margaret Clagett-Dame, PhD will continue in her role as Executive Vice President.

Deltanoid Pharmaceuticals, Inc. CEO, Douglas Jermasek
"I am proud of the accomplishments of Deltanoid in developing our lead compound through phase 2 and in positioning two other compounds for phase 2 clinical trials," said Dr. DeLuca. "As we now advance our lead program, DP001 for the treatment of secondary hyperparathyroidism (SHPT) to phase 3 clinical development and ultimately commercialization, I am pleased to be turning over the reins to Doug, who brings a 20 year track record of biopharmaceutical industry success and proven leadership in the renal space."

"I'm very excited by the opportunity to lead Deltanoid as we complete the final stage of clinical development of DP001 and begin to shape the commercial opportunity for this uniquely differentiated product with its best-in-class profile," said Mr. Jermasek.

Mr. Jermasek has over 20 years of biopharmaceutical industry experience. In his past role as Senior Vice President & General Manager of Genzyme/Sanofi's global renal business, he drove sales over $ billion, establishing Renvela® as the standard of care for the treatment of hyperphosphatemia for patients with chronic kidney disease (CKD) and achieving "blockbuster" status globally. Outside of his 12 years at Genzyme/Sanofi Renal, Mr. Jermasek has held positions of progressive responsibility at Hybritech/Lilly, Abbott Laboratories, Agouron/Pfizer, Prometheus, and most recently as Head of North America at Intercept. Mr. Jermasek received an M.B.A. from the Marriott School of Management and a B.S. in biological science from Brigham Young University.

About Deltanoid Pharmaceuticals, Inc.

Founded out of the biochemistry lab of Hector F. DeLuca at the University of WisconsinMadison, Deltanoid Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform the health outcomes of patients with diseases of the kidney, bone, and skin. For more information about Deltanoid, please visit http://www.deltanoid.com.

Photo - http://photos.prnewswire.com/prnh/20160202/328667

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/deltanoid-pharmaceuticals-announces-appointment-of-douglas-jermasek-as-chief-executive-officer-300213717.html

SOURCE Deltanoid Pharmaceuticals, Inc.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.